Clinical Trial Search

Primary: Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3 — 78; 77; 78; 77 Participants

Primary: Change in Percent Collagen I Deposition on Lymph Node Pathology From Baseline to Week 48 — -2.44; -6.08 percent area stain positive — p=0.97

Primary: Number of Participants Who Received At Least 1 Infusion of Sipuleucel-T in Men With Metastatic Castrate-resistant Prostate Cancer (CRPC) — 98 participants

Primary: Number of Subjects With Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitides Serogroups A, C , W-135, Y (hSBA-MenA, hSBA-MenC , hSBA-MenW -135…

Primary: Mean Pain Intensity (NRS) — 5.93; 5.89 units on a scale — p=0.834

Primary: Normal Biodistribution of 68Ga-DOTA-Bombesin — 2.28; 121.55; 0.08; 0.10 SUV-mean

Primary: Number of Subjects With Symptomatic Intracerebral Hemorrhage — 1; 1 Participants

Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects

Primary: Percent Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status at 16 Weeks — 10.1053; 3.6364 percentage of change

Primary: 8-Week Progression-Free Rate — 0.0; 8.3 percentage of participants

Primary: 2 Year Disease-free Survival . — 9 percentage of participants

Primary: Resistance Mechanism — 23; 1; 3; 4 participants

Primary: Percentage of Participants Experiencing Adverse Events (AEs) — 100.0 Percentage of participants

Primary: Change From Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -14.37; -14.40; -13.18 units on a scale — p=0.630

Primary: Mean Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to the End of 8 Weeks of Therapy. — 32.4; 30.4; 21.7; 19.0 units on a scale